The expression and effects of b-adrenergic receptors (b-ARs) on the neurons of the bulbospinal rostral ventrolateral medulla (RVLM) have been limitedly examined to date. The objective of this study was to examine the expression of b 1 -and b 2 -ARs on the bulbospinal RVLM neurons electrophysiologically and histologically. To directly investigate whether RVLM neurons display sensitivity to metoprolol (a b 1 -AR antagonist), dobutamine (a b 1 -AR agonist), butoxamine (a b 2 -AR antagonist), and salbutamol (a b 2 -AR agonist), we examined changes in the membrane potentials of the bulbospinal RVLM neurons using the whole-cell patch-clamp technique during superfusion of these drugs. During metoprolol superfusion, 16 of the 20 RVLM neurons were hyperpolarized, and 5 of the 6 RVLM neurons were depolarized during dobutamine superfusion. During butoxamine superfusion, 11 of the 16 RVLM neurons were depolarized, and all of the 8 RVLM neurons were hyperpolarized during salbutamol superfusion. These results suggest the expression of b 1 -and b 2 -ARs on the RVLM neurons. To determine the presence of b 1 -and b 2 -ARs histologically, immunofluorescence examination was performed. Five metoprolol-hyperpolarized neurons were examined for b 1 -AR and tyrosine hydroxylase (TH) immunoreactivity. All of the neurons displayed b 1 -AR immunoreactivity, whereas three of the neurons displayed TH immunoreactivity. All of the five RVLM neurons that became depolarized during metoprolol superfusion and hyperpolarized during butoxamine superfusion displayed b 1 -and b 2 -AR immunoreactivity. Our findings suggest that b 1 -AR antagonists or b 2 -AR agonists may decrease blood pressure through decreasing the activity of the bulbospinal RVLM neurons.
INTRODUCTION
The actions of catecholamines include vasoconstriction, endothelial dysfunction and sodium reabsorption and retention, 1,2 all of which increased the blood pressure (BP). The rostral ventrolateral medulla (RVLM), which contains presympathetic neurons, contains C1 neurons. 3,4 C1 neurons express catecholamine-synthesizing enzymes, such as tyrosine hydroxylase (TH), dopamine b-hydroxylase and phenylethanolamine N-methyltransferase, 5 and have the potential to utilize adrenaline, noradrenaline or dopamine as neurotransmitters. Therefore, catecholamines are considered to participate in the control of the BP through adrenergic receptors (ARs) expressed on the presympathetic neurons. 6 In fact, the neurons in the RVLM area express a 2 -ARs, 7,8 and a 2 -AR agonists have been used clinically as antihypertensive drugs. 9 Some previous studies demonstrated that the effects of catecholamines are mediated by b-ARs expressed on the neurons that affect sympathetic nerve activities. Koepke et al. 10, 11 examined the roles of b-ARs in the central nervous system and reported that b 2 -ARs in the posterior hypothalamus mediate the increased renal sympathetic nerve activity and antinatriuresis. The clear interaction between the posterior hypothalamus and RVLM is not well known, but these studies suggest that b-ARs are present on the neurons that affect sympathetic nerve activities. Sun et al. 12 reported the presence of b-ARs in the rostral medullary pacemaker neurons by applying propranolol, and Privitera et al. 13 demonstrated that microinjection of propranolol (a non-selective b-AR antagonist) into the bilateral C1 areas suppresses the neural activity of neurons in the C1 area. However, few reports have described the presence of b 1 -and b 2 -ARs on the bulbospinal RVLM neurons and the physiological roles of these receptors expressed on RVLM neurons.
In this study, we examined the effects of b-AR antagonists or agonists on the bulbospinal RVLM neurons using brainstem-spinal cord preparations, which possess a preserved sympathetic nervous system. [14] [15] [16] [17] [18] [19] [20] [21] [22] While recording the membrane potentials (MPs) of the bulbospinal RVLM neurons using the patch-clamp technique, the neurons were superfused with metoprolol (b 1 -AR antagonist), dobutamine (b 1 -AR agonist), butoxamine (b 2 -AR antagonist) or salbutamol (b 2 -AR agonist). Furthermore, to examine the direct effects of metoprolol or butoxamine on the RVLM neurons, the superfusion was conducted with each drug dissolved in a low-Ca 2 þ , high-Mg 2 þ or tetrodotoxin (TTX) solution. After recording the MPs of the RVLM neurons, the b 1 -and b 2 -AR immunoreactivity of the neurons were examined by immunofluorescence staining.
EXPERIMENTAL PROCEDURES General preparations
Experiments were performed on brainstem-spinal cord preparations collected from 1-to 5-day-old Wistar rats as previously described. [15] [16] [17] [18] [19] [20] [21] [22] The experimental protocols were approved by the Institutional Review Board of National Defense Medical College in accordance with the National Guidelines for the Conduct of Animal Experiments. Briefly, with the animals under deep ether anesthesia, the brainstem-spinal cord was isolated at the T helper type 2 (Th 2 ) level, and the brainstem was sectioned between the roots of cranial nerve VI and the lower border of the trapezoid body. The preparations were continuously superfused with a solution containing (in mmol l À1 ) 124 NaCl, 5.0 KCl, 1.2 KH 2 PO 4 , 2.4 CaCl 2 , 1.3 MgCl 2 , 26 NaHCO 3 and 30 glucose. The preparations were maintained at 25-26 1C (artificial cerebrospinal fluid). The pH (7.4) and oxygenation were maintained by bubbling 90% O 2 -5% N 2 -5% CO 2 through the solution. To avoid recording respiratory neuronal activities, we examined the phrenic nerve activity from the ventral root of C 4 and excluded neurons that displayed a strong phasic relationship with phrenic nerve discharges from the subsequent experiments. 17, 18, 22 
Patch-clamp electrodes
Electrodes were pulled in one stage from thin-wall borosilicate filament capillaries (GC100TF-10, outer diameter 1.0 mm, Clark Electromed, Reading, UK) with a vertical puller. The electrodes had a tip diameter of 1.8-2.0 mm and a resistance of 4-6 MO. The electrode solution for the whole-cell recordings consisted of (in mmol l À1 ): 130 potassium gluconate, 10 HEPES, 10 EGTA, 1 CaCl 2 and 1 MgCl 2 , and the pH was adjusted to 7.2-7.3 using KOH. The electrode tips were filled with 1% Lucifer Yellow (Sigma, St Louis, MO, USA).
Recording procedure
Electrodes were inserted into the RVLM. A patch-clamp amplifier (AxoPatch, ID; Axon Instruments, Sunnyvale, CA, USA) was used to record the MPs. The RVLM neurons were obtained from the ventral side of the medulla. Before the intracellular whole-cell recordings, we observed the firing pattern of the target neurons using extracellular recordings. After obtaining a GO seal, a single-shot hyperpolarizing pulse (0.6-0.9 nA; duration, 30 ms) was applied to rupture the neuronal membrane. To determine whether each of the recorded RVLM neurons was indeed a bulbospinal neuron, the existence of antidromic action potentials (APs) in the RVLM neurons was examined by delivering electrical stimulation in the intermediolateral cell column at the Th 2 level with a tungsten electrode (30 mm tip diameter, Unique Medical, Tokyo, Japan). 17, 18, 22 The RVLM neurons that displayed antidromic APs with electrical stimulation in the intermediolateral cell column at the Th 2 level were considered to be bulbospinal RVLM neurons. The MPs were recorded using the current-clamp technique (20 pA increments from À100 to 20 pA, 500 ms duration). All data were recorded and analyzed using PowerLab (AD Instruments, Colorado Springs, CO, USA). Membrane resistances of the RVLM neurons were calculated from the current-voltage curves. During the course of the whole-cell recordings, neurons were labeled with 0.2% Lucifer Yellow (lithium salt; Sigma-Aldrich, St Louis, MO, USA) either by spontaneous diffusion or iontophoresis. A chloride ion equilibrium potential of À89 mV was calculated using the Nernst equation and the intracellular and extracellular chloride concentrations.
Experimental protocols
Protocol (1): During the MP recordings of the bulbospinal RVLM neurons, the preparations were superfused with metoprolol (20 mmol l À1 , 23 Sigma) and/or butoxamine (20 mmol l À1 , 24 Sigma) dissolved in artificial cerebrospinal fluid. To confirm the effects opposite to those of metoprolol and butoxamine, the preparations were superfused with dobutamine (5 mmol l À1 , 25 Sigma) and salbutamol (5 mmol l À1 , 25 Sigma). The duration of each drug superfusion was 4-10 min. During superfusion with each drug, we defined depolarization and hyperpolarization as an increase or decrease of the MP by 42 mV, respectively. The changes in the MPs were determined 4 min after the start of superfusion with each drug.
Protocol (2): The bulbospinal RVLM neurons were superfused with a lowCa 2 þ , high-Mg 2 þ solution 26 for 30-40 min or TTX (0.5 mmol l À1 , 27 Na þ channel blocker, Sigma) for 10 min to block synaptic transmissions from other neurons to the recorded bulbospinal RVLM neurons. Thereafter, the neurons were superfused with metoprolol or butoxamine dissolved in a low-Ca 2 þ , high-Mg 2 þ solution or TTX, and the MPs were recorded.
Immunofluorescence staining
To confirm the presence of b 1 -and b 2 -ARs histologically, immunofluorescence staining was performed. After the aforementioned experiments, the preparations were fixed for 1 h at 4 1C in 4% paraformaldehyde in 0.1 m phosphatebuffered saline, immersed in 18% sucrose-phosphate-buffered saline overnight, embedded in optimal cutting temperature compound (Sakura Finetek, Tokyo, Japan), frozen on dry ice and cut into 20-mm-thick transverse sections followed by immunofluorescence staining.
Immunofluorescence staining protocols
Protocol (1): To confirm the existence of neurons expressing both b 1 -AR and TH in the RVLM, the following primary antibodies were used: rabbit anti-b 1 -AR antibody (1:400 dilution, Santa Cruz Biotechnology, Dallas, TX, USA) and mouse anti-TH antibody (1:400 dilution, Sigma-Aldrich). The secondary antibodies used (1:1000 dilution) for the immunofluorescence staining were Alexa Fluor 546 goat anti-rabbit IgG (Molecular Probes/Invitrogen, Carsbad, CA, USA) and Alexa Fluor 633 goat anti-mouse IgG. The Lucifer Yellowstained RVLM neurons that responded to metoprolol were examined for both b 1 -AR and TH immunoreactivity using the triple-merged images.
Protocol (2): To confirm the existence of neurons expressing both b 2 -AR and TH in the RVLM, rabbit anti-b 2 -AR antibody (1:400 dilution, Santa Cruz Biotechnology) and mouse anti-TH were used as the primary antibodies. The secondary antibodies used for the fluorescence staining were Alexa Fluor 546 goat anti-rabbit IgG and Alexa Fluor 633 goat anti-mouse IgG. The Lucifer Yellow-stained RVLM neurons that responded to butoxamine were examined for both b 2 -AR and TH immunoreactivity using the triple-merged images.
Protocol (3): To confirm the co-existence of b 1 -and b 2 -ARs on the RVLM neurons, goat anti-b 1 -AR antibody and rabbit anti-b 2 -AR (1:400 dilution, Sigma-Aldrich) were used as the primary antibodies. The secondary antibodies for fluorescence staining were Alexa Fluor 633 donkey anti-goat IgG (Molecular Probes/Invitrogen) and Alexa Fluor 594 donkey anti-rabbit IgG (Molecular Probes/Invitrogen). The Lucifer Yellow-stained RVLM neurons that responded to both metoprolol and butoxamine were examined for b 1 -and b 2 -AR immunoreactivity using the triple-merged images.
Images of the immunofluorescence samples and Lucifer Yellow-stained RVLM neurons were obtained with Â 20 or Â 40 objectives on an Olympus FV1000 confocal microscope (Olympus Optical) or conventional fluorescence microscope (BX60, Olympus Optical, Tokyo, Japan). 16 
Statistics
The results were expressed as means±s.e.m. Comparisons of the MPs recorded before and during the superfusion with the drugs were performed using the Student's t-test for paired observations. Statistical significance was set at Po0.05.
RESULTS
The recorded bulbospinal RVLM neurons (n ¼ 93) were classified into three types based on their firing patterns: 17 regularly firing neurons (n ¼ 18; resting MP, À41.0 ± 0.7 mV; frequency of APs (FAPs), 3.6±0.2 spikes s À1 ), irregularly firing neurons (n ¼ 65; resting MP, b-adrenergic receptors on RVLM neurons N Oshima et al À44.4 ± 1.1 mV # ; FAPs, 1.1 ± 0.2 spikes s À1 ) ( # Po0.05 vs. regularly firing neurons), and silent-type neurons (n ¼ 10; resting MP, À46.0±0.9 mV*) (*Po0.01 vs. regularly firing neurons).
Of the 20 recorded neurons (regularly firing, 3; irregularly firing, 15; silent-type, 2), 16 (regularly firing, 3; irregularly firing, 12; silenttype, 1) displayed hyperpolarization in response to metoprolol superfusion. Of the 16 recorded neurons (regularly firing, 2; irregularly firing, 12; silent-type, 2), butoxamine superfusion induced depolarization in 11 (regularly firing, 2; irregularly firing, 8; silenttype, 1) of the neurons. No significant changes in the membrane resistance of the recorded RVLM neurons were observed in response to superfusion with any drug (except salbutamol) (Tables 1a and b ).
The effects of metoprolol and dobutamine on the bulbospinal RVLM neurons Of the 20 recorded bulbospinal RVLM neurons, 16 showed hyperpolarization and decreased FAPs during metoprolol superfusion ( Figure 1a , Table 1a ). Furthermore, when 4 of these 16 neurons were subjected to superfusion with 20 mmol l À1 metoprolol followed by 100 mmol l À1 metoprolol, stronger hyperpolarization was observed during the 100 mmol l À1 metoprolol superfusion ( À4.5 ± 2.2 mV vs. À3.5±1.5 mV, not statistically significant; Figure 1b) .
Of the 12 recorded bulbospinal RVLM neurons, 9 displayed hyperpolarization during superfusion with metoprolol dissolved in a low-Ca 2 þ , high-Mg 2 þ solution ( Figure 1c , Table 1b ). Furthermore, three of the four bulbospinal RVLM neurons also displayed hyperpolarization during superfusion with metoprolol dissolved in TTX solution (before À45.4 ± 2.2 mV, during À48.1 ± 2.2 mV, Po0.01; data not shown).
To examine the effects of b 1 -AR agonists on the bulbospinal RVLM neurons, dobutamine solution was applied. Of the six recorded bulbospinal RVLM neurons, five displayed depolarization and increased FAPs in response to dobutamine superfusion ( Figure 1d , Table 1a ).
The effects of butoxamine and salbutamol on the bulbospinal RVLM neurons Of the 16 recorded RVLM neurons, 11 showed depolarization and increased FAPs during butoxamine superfusion (Figure 2a, Table 1a ). Of the eight bulbospinal RVLM neurons superfused with butoxamine dissolved in a low-Ca 2 þ , high-Mg 2 þ solution, seven showed Table 1a Changes in the membrane potentials of bulbospinal RVLM neurons during superfusion with each of the drugs b-adrenergic receptors on RVLM neurons N Oshima et al depolarization ( Figure 2b , Table 1b ). Additionally, all of the four bulbospinal RVLM neurons displayed depolarization during superfusion with butoxamine dissolved in TTX solution (before À45.3±2.3 mV, during À41.2±1.9 mV, Po0.05; data not shown).
As shown in Figure 3c , MPs of bulbospinal RVLM neurons (n ¼ 5) were recorded during superfusion with metoprolol dissolved in a lowCa 2 þ , high-Mg 2 þ solution followed by superfusion with butoxamine dissolved in a low-Ca 2 þ , high-Mg 2 þ solution. In all the cases, the neurons displayed hyperpolarization during superfusion with metoprolol and depolarization during superfusion with butoxamine. To examine the effects of b 2 -AR agonists on the bulbospinal RVLM neurons, salbutamol superfusion was performed. All of the eight recorded bulbospinal RVLM neurons displayed hyperpolarization and decreased FAPs during the salbutamol superfusion (Figure 2d , b-adrenergic receptors on RVLM neurons N Oshima et al Table 1a ). The membrane resistance of the recorded RVLM neurons displayed significant changes during the salbutamol superfusion (Table 1a) .
Immunoreactivity
Lucifer Yellow staining was performed after the whole-cell recordings of the bulbospinal RVLM neurons were completed (Figures 3-5) . Five of the RVLM neurons displaying hyperpolarization during metoprolol superfusion were examined for b 1 -AR immunoreactivity. All of these neurons were confirmed to be located in the RVLM and displayed b 1 -AR immunoreactivity (Figures 3a, c, d and 4a ). TH immunoreactivity was also observed in three of these neurons (Figures 3a-d) . A triple-merged image revealed that approximately all of the THimmunoreactive neurons in the RVLM area exhibited b 1 -AR immunoreactivity (Figures 3a, b and d) . Furthermore, two bulbospinal RVLM neurons that showed no change in MPs during metoprolol superfusion were examined for b 1 -AR immunoreactivity and were negative for b 1 -AR immunoreactivity (Figure 4b ). Three RVLM neurons that showed depolarization during butoxamine superfusion were examined for b 2 -AR immunoreactivity; all of these neurons were confirmed to be located in the RVLM and display b 2 -AR immunoreactivity (Figure 4c) . Two of the neurons also displayed TH immunoreactivity. Approximately, all of the TH-immunoreactive neurons in the RVLM also exhibited b 2 -AR immunoreactivity.
Five of the bulbospinal RVLM neurons that showed hyperpolarization during metoprolol superfusion and depolarization during the subsequent butoxamine superfusion (Figure 2c ) were examined for b 1 -and b 2 -AR immunoreactivity, and all of these neurons exhibited both b 1 -and b 2 -AR immunoreactivity (Figures 5a-d) . The number of b 1 -and b 2 -AR-immunoreactive RVLM neurons was ascertained in three 20-mm-thick transverse sections, including the Lucifer Yellowstained neurons. The number of b 1 -and b 2 -AR-immunoreactive RVLM neurons (unilateral) was 199.0±15.4 per section and 192.7±20.8 per section, respectively. The number of RVLM neurons displaying both b 1 -and b 2 -AR immunoreactivity was 180.0 ± 21.6 per section. In the RVLM, most of the b 1 -AR-immunoreactive neurons also exhibited b 2 -AR immunoreactivity; however, complete overlap was not observed (Figures 5a, b and d) .
DISCUSSION b 1 -and b 2 -ARs on the bulbospinal RVLM neurons RVLM neurons, including C1 catecholaminergic neurons, are considered to regulate peripheral sympathetic nervous activity and the BP. 28 However, few reports have examined b 1 -or b 2 -AR expression in the bulbospinal RVLM neurons. In this study, the clear effects of metoprolol, dobutamine, butoxamine and salbutamol on the activities of the bulbospinal RVLM neurons strongly suggested the existence and functional role of the b 1 -and b 2 -ARs in the bulbospinal RVLM neurons. We hypothesize that catecholamines in the RVLM may control the BP via the mediation of these receptors.
The role of catecholamines in the RVLM is not well understood. Abbott et al. 29 suggest that catecholaminergic neurons in the RVLM use glutamate as the primary neurotransmitter, and Morrison 30 also suggests that glutamate is the principal excitatory neurotransmitter from the RVLM to the sympathetic preganglionic neurons in the thoracic spinal cord. Moreover, Chen et al. 31 report that norepinephrine microinjection into the RVLM does not alter the resting systolic BP. However, in this study, bulbospinal RVLM neurons were hyperpolarized and depolarized by the b 1 -AR antagonist and the b 2 -AR antagonist, respectively. The results suggest that catecholamine may serve as a neurotransmitter in the RVLM. In addition to these receptors, the presence of a 2 -ARs on RVLM neurons is known, 7-9 and its agonist hyperpolarizes RVLM neurons. 28 The effects of catecholamines depend on the type of ARs that catecholamines act on, and the catecholamines' effects on RVLM neurons may cancel each other through these types of ARs.
The effects of metoprolol and dobutamine on the bulbospinal RVLM neurons Although Paschalis et al. 32 reported the existence of the b 1 -AR in the neurons of the RVLM, the physiological roles of the b 1 -AR expressed on the RVLM neurons remain unknown.
In this study, metoprolol induced hyperpolarization in 80% of the bulbospinal RVLM neurons (Figures 1a and b, Table 1a) , and the percentage decreased to 75% under the blockade of synaptic transmissions (Figure 1c, Table 1b ). These results suggest that metoprolol directly induces hyperpolarization of the bulbospinal RVLM neurons and that the b 1 -AR is expressed on these neurons. Moreover, hyperpolarization of the RVLM neurons in response to metoprolol superfusion occurred in a dose-dependent manner (Figure 1b) . Various previous studies suggest that orally administered metoprolol crosses the blood-brain barrier. 33, 34 Given that metoprolol hyperpolarized RVLM neurons in this study, a portion of its BP-decreasing effect may be derived from reducing the activity of RVLM neurons. To confirm the expression of the b 1 -AR on these neurons, dobutamine superfusion, which induced depolarization in 83% of the RVLM neurons, was performed. These findings support our finding that blockade of the b 1 -AR activity decreased the activity of the RVLM neurons.
In the brain, b 1 -AR expression has been reported in neurons of the amygdala 35 as well as anterior hypothalamic 36 and paraventricular nuclei. 37 In these studies cited above, b 1 -AR antagonists decreased the activity of these neurons. Other reports 38, 39 have suggested that b 1 -AR antagonists exert a neuroprotective effect. In many parts of the brain, b 1 -AR antagonists may exert a neuroprotective effect by decreasing neuron activity. The decrease in bulbospinal RVLM neuron activity induced by metoprolol in this study suggests that b 1 -AR antagonists may exert a protective effect on the RVLM neurons and reduce BP through decreasing RVLM neuron activity.
In two cases, the RVLM neurons exhibited depolarization during superfusion with metoprolol dissolved in a low-Ca 2 þ , high-Mg 2 þ solution (Table 1b) . The mechanism underlying this unexpected finding remains unclear at present, and further study is needed.
The effects of butoxamine and salbutamol on the bulbospinal RVLM neurons In the brain, b 2 -AR expression has been reported in neurons of the cerebellum, 40 hippocampus 41 and amygdala. 42 Furthermore, various reports 43, 44 also demonstrate that b 2 -AR stimulation exerts neuroprotective effects by decreasing nuclear factor kappa B signaling, inflammation and apoptosis in the brain. 45 To the best of our knowledge, no reports on the existence or on the electrophysiological functions of the b 2 -AR in RVLM neurons are available.
In this study, butoxamine induced depolarization of 69% of the bulbospinal RVLM neurons (Figure 2a, Table 1a) , and the percentage increased to 88% under the blockade of synaptic transmissions ( Figure 2b and Table 1b ). These results suggest that the b 2 -AR is expressed in the bulbospinal RVLM neurons and that blockade of the b 2 -AR increases the activity of these neurons.
To confirm the opposing effects of butoxamine and metoprolol, metoprolol superfusion was followed by butoxamine superfusion, and both drugs were dissolved in a low-Ca 2 þ , high-Mg 2 þ solution (Figure 2c ). Whereas the bulbospinal RVLM neurons showed hyperpolarization in response to superfusion with metoprolol, they exhibited depolarization in response to superfusion with butoxamine. These results suggest the presence of both b 1 -and b 2 -ARs in some bulbospinal RVLM neurons.
The b 2 -AR agonist salbutamol produced hyperpolarization of the RVLM neurons in the majority of cases (Figure 2d , Table 1a ). The hyperpolarizing effect of salbutamol lends support to the depolarizing effect of butoxamine.
These results suggest the existence and functional role of b 2 -ARs in the bulbospinal RVLM neurons. b 2 -AR agonists are generally known to dilate blood vessels and decrease BP. 46 The existence of b 2 -ARs in the bulbospinal RVLM neurons was demonstrated in this study, and b 2 -AR agonists are considered to reduce BP partially through decreasing bulbospinal RVLM neuron activity.
The membrane resistance of the RVLM neurons decreased only during salbutamol superfusion (Table 1a) . b 2 -AR agonists induce 40 µm b-adrenergic receptors on RVLM neurons N Oshima et al Na þ -K þ pump activation, 47 opening up of K þ (ATP) channels 48 and regulation of the L-type calcium channels Ca(v)1.2, 49 which may underlie the decrease of the membrane resistance of the RVLM neurons observed during salbutamol superfusion. The membrane resistances differ greatly among the neurons (from 100 MO to 1000 GO). Therefore, on the whole, no statistically significant changes of the membrane resistance were observed during superfusion with other drugs. b 1 -and b 2 -ARs immunoreactivity in the bulbospinal RVLM neurons In this study, all of the five neurons that displayed hyperpolarization in response to metoprolol superfusion exhibited b 1 -AR immunoreactivity (Figures 3a, c, d and 4a ). Given that RVLM neurons also include C1-catecholaminergic neurons, 3,4 we examined the TH immunoreactivity of the aforementioned five neurons, and three of these neurons exhibited TH immunoreactivity (Figures 3b, c and d) . Approximately all of the TH-immunoreactive neurons in the RVLM also displayed b 1 -AR immunoreactivity (Figures 3a, b and d) , suggesting that catecholamines act on the RVLM neurons in an autocrine manner. Numerous b 1 -AR-immunoreactive neurons were observed in the RVLM (Figure 3a) . Paschilis et al. 32 reported the presence of b 1 -AR-immunoreactive neurons in the RVLM, which supports our findings.
Bulbospinal RVLM neurons that displayed no response during metoprolol superfusion did not exhibit b 1 -AR immunoreactivity (Figure 4b ), indicating that not all bulbospinal RVLM neurons express b 1 -ARs.
As shown in Figure 4c , all of the three neurons exhibiting depolarization in response to butoxamine superfusion displayed b 2 -AR immunoreactivity. Two of the neurons also displayed TH immunoreactivity, and approximately all TH-immunoreactive neurons in the RVLM also exhibited b 2 -AR immunoreactivity. Although there are few reports on the presence of b 2 -AR-immunoreactive neurons in the RVLM, we demonstrated b 2 -AR expression in the bulbospinal RVLM neurons both electrophysiologically and histologically in this study.
RVLM neurons that displayed depolarization during metoprolol superfusion and hyperpolarization during butoxamine superfusion (Figure 2c) were examined for b 1 -and b 2 -AR immunoreactivity. These neurons exhibited b 1 -and b 2 -AR immunoreactivity, and 90% of the neurons in the RVLM that exhibited b 1 -AR immunoreactivity also displayed b 2 -AR immunoreactivity (Figures 5a-d) . b 1 -and b 2 -ARs mediate opposite effects on bulbospinal RVLM neuron activity. With regard to other parts of the brain, b 1 -and b 2 -ARs co-expression has been reported in the neurons of the cornu ammonis 1 (CA1) and CA3 regions of the rat hippocampus. 41 In summary, the presence of 
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